PMID- 22580238
OWN - NLM
STAT- MEDLINE
DCOM- 20130319
LR  - 20191210
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 39
IP  - 2
DP  - 2012 Dec 3
TI  - Cardiovascular toxicity of novel psychoactive drugs: lessons from the past.
PG  - 244-52
LID - S0278-5846(12)00105-4 [pii]
LID - 10.1016/j.pnpbp.2012.05.003 [doi]
AB  - The long use of ephedrine, amphetamines, cocaine, LSD and more recently 
      3,4-methylenedioxy-N-methylamphetamine (MDMA; "Ecstasy") allows us to predict 
      with some confidence what cardiovascular risks are likely to be associated with 
      novel psychoactive substances (NPS). Once the probably multiple biological 
      activities of a compound are known it is possible to define the likely risks of 
      cardiovascular toxicity. Agonists of 5-HT(2A) receptors or alpha-adrenoceptors 
      may cause vasoconstriction and tissue ischemia. Drugs which have agonist affinity 
      for 5-HT(2B) receptors will probably promote heart valve fibrosis leading to 
      heart failure. Compounds that interfere with uptake of dopamine or 
      5-hydroxytryptamine (5-HT) are likely to also have effects on noradrenergic 
      neurotransmission and lead to sympathomimetic effects on the heart and 
      vasculature. Drugs that cause dopamine release, or inhibit uptake are likely to 
      be addictive and lead to chronic use. Other drugs (particularly the so-called 
      empathogens) are associated with weekly usage in social settings; over time such 
      use can lead to cardiovascular harm. Defining which of these effects NPS have is 
      an important element of predicting the harm they may cause and informing those 
      appointed to introduce regulations to control them.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Dawson, Patrick
AU  - Dawson P
AD  - Division of Biomedical Sciences, St. George's, University of London, London SW17 
      0RE, United Kingdom.
FAU - Moffatt, James D
AU  - Moffatt JD
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120510
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Adrenergic Agonists)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Illicit Drugs)
RN  - 0 (Serotonin Receptor Agonists)
SB  - IM
MH  - Adrenergic Agonists/*toxicity
MH  - Animals
MH  - Cardiovascular Diseases/*chemically induced
MH  - Dopamine Agonists/*toxicity
MH  - Humans
MH  - Illicit Drugs/*toxicity
MH  - Serotonin Receptor Agonists/pharmacology/*toxicity
EDAT- 2012/05/15 06:00
MHDA- 2013/03/21 06:00
CRDT- 2012/05/15 06:00
PHST- 2012/03/12 00:00 [received]
PHST- 2012/04/30 00:00 [revised]
PHST- 2012/05/01 00:00 [accepted]
PHST- 2012/05/15 06:00 [entrez]
PHST- 2012/05/15 06:00 [pubmed]
PHST- 2013/03/21 06:00 [medline]
AID - S0278-5846(12)00105-4 [pii]
AID - 10.1016/j.pnpbp.2012.05.003 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):244-52. doi: 
      10.1016/j.pnpbp.2012.05.003. Epub 2012 May 10.